Mather Group’s PTC Therapeutics PTCT Stock Holding History

Mather Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.89K	Buy	+60	New	+$4.37K	﹤0.01%	1866

Other funds holding PTCT

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Mather Group's PTCT Position: Q3 2026 in Review

Mather Group opened a new position in PTC Therapeutics (PTCT) in Q3 2026: 60 shares worth $3.89K. The stake represents ﹤0.01% of the portfolio and ranks #1866 among its holdings.

50 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

Mather Group held 60 shares of PTC Therapeutics worth $3.89K as of Q3 2026.
PTC Therapeutics was a new Mather Group position in Q3 2026.
PTC Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1866 holding.
50 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.